In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Two columns page  

Dyslipidaemias (Management of)

ESC Clinical Practice Guidelines

These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention.

Wach the webcast of the joint ESC Guidelines on the Management of  Dyslipidemias presented at the ESC Congress 2011.

Watch the recording of the ESC Webinar on the ESC Guidelines

Warning Simvastatin

Primary care
Hypertension
Dyslipidemia
Guidelines version available to download
Published in 2011
Reference European Heart Journal (2011) 32:1769-1818
Published in 2012
Reference Essential Messages Dyslipidaemias
Published in 2011
Reference Table of Contents
  • PDA
  • Published in 2012
    Reference Download the PDA version of the Pocket Guidelines
    Published in 2012
    Reference ESC_Slide_set_on_Dyslipidaemias
    Published in 2011
    Reference ESC/EAS CME Questions Dyslipidaemias
    Published in 2011
    Reference ESC/EAS Dyslipidemias addenda
    Authors

    Zeljko Reiner (ESC Chairperson), Alberico L. Catapano (EAS Chairperson), Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund,Stefan Agewall (Norway), Eduardo Alegria (Spain), M. John Chapman (France), Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood (UK).

    Table of contents: Full Text (ESC Clinical Practice Guidelines)

    Table of Contents

    • 1. Preamble
    • 2. Introduction
    • 3. Total cardiovascular  risk
    • 4. Evaluation of laboratory lipid and apolipoprotein parameters
    • 5. Treatment targets
    • 6. Lifestyle modifications to imporve the plasma lipid profile
    • 7. Drugs for treatment of hypercholesterolaemia
    • 8.Drugs for treatment of hypertriglyceridaemia
    • 9.Drugs affecting high-desity lipoprotein
    • 10.Management of dyslipidaemai in different clinical settings
    • 11.Monitoring of lipids and enzymes in patients on lipid lowering drug therapy
    • 12.How to improve adherence to lifestyle changes and compliance with drug therapy
    • 13.References

     

     

     

    Back to top

    Who we are

    What we do

    How we work

    More ESC